Your browser doesn't support javascript.
Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
Scherbaum, Raphael; Kwon, Eun Hae; Richter, Daniel; Bartig, Dirk; Gold, Ralf; Krogias, Christos; Tönges, Lars.
  • Scherbaum R; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Kwon EH; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Richter D; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Bartig D; DRG MARKET, Osnabrück, Germany.
  • Gold R; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Krogias C; Neurodegeneration Research, Protein Research Unit Ruhr (PURE), Ruhr University Bochum, Bochum, Germany.
  • Tönges L; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Mov Disord ; 36(5): 1049-1057, 2021 05.
Article in English | MEDLINE | ID: covidwho-1212768
ABSTRACT

BACKGROUND:

Comprehensive, nationwide data regarding Parkinson's disease (PD) hospitalizations, coronavirus disease 2019 (COVID-19) in-hospital frequency, and COVID-19-associated inpatient mortality during the first wave of the COVID-19 pandemic are not available.

OBJECTIVE:

To provide a nationwide analysis on hospitalized PD patients in Germany and evaluate the impact of the COVID-19 pandemic.

METHODS:

We conducted a cross-sectional study using an administrative claims database covering 1468 hospitals and 5,210,432 patient hospitalizations including a total of 30,872 COVID-19+ cases between January 16 and May 15, 2020.

RESULTS:

Compared to 2019, hospitalizations for PD transiently decreased by up to 72.7% in 2020. COVID-19 frequency was significantly higher in the population of 64,434 PD patients (693 being COVID-19+ ) than in non-PD patients (1.1% vs. 0.6%, P < 0.001), especially in subjects with advanced age (≥ 65 years). Regarding established COVID-19 risk comorbidities, COVID-19+ inpatients with PD showed higher incidences than non-PD COVID-19+ subjects, particularly hypertension and chronic kidney disease. Advanced age and male sex were significantly more frequent in COVID-19+ than in COVID-19- PD patients. The COVID-19 inpatient mortality rate was much higher in PD patients than in non-PD patients (35.4% vs. 20.7%, P < 0.001), especially in patients aged 75-79 years. Of note, overall inpatient mortality of PD patients was significantly higher in 2020 than in 2019 (5.7% vs. 4.9%, P < 0.001).

CONCLUSIONS:

PD inpatients are more frequently affected by COVID-19 and suffer from increased COVID-19-associated mortality in comparison to non-PD patients. More comprehensive studies are needed to assess the significance of associated comorbidities for COVID-19 risk and mortality in PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Parkinson Disease / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Humans / Male Country/Region as subject: Europa Language: English Journal: Mov Disord Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: Mds.28586

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Parkinson Disease / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Humans / Male Country/Region as subject: Europa Language: English Journal: Mov Disord Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: Mds.28586